AO-176 in Multiple Solid Tumor Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Solid Tumor

In brief

This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.

Key facts

Study ID

NCT03834948

Run by

Arch Oncology

People needed

57

Starts

2019-02-04

Expected to finish

2023-02-15

Last updated by the study team

2023-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Southern California — Los Angeles, California, United States
• University of California San Francisco — San Francisco, California, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Oklahoma University, Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• Oregon Health Science University — Portland, Oregon, United States
• Sidney Kimmel Cancer Center, Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• University of Virginia — Charlottesville, Virginia, United States
• Virginia Cancer Specialists — Fairfax, Virginia, United States
• Northwest Medical Specialties — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.